Ignite Creation Date:
2025-12-24 @ 2:38 PM
Ignite Modification Date:
2026-06-04 @ 9:25 AM
Study NCT ID:
NCT02659059
Status:
COMPLETED
Last Update Posted:
2023-04-05
First Post:
2016-01-15
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Nivolumab in Combination With Ipilimumab (Part 1); Nivolumab Plus Ipilimumab in Combination With Chemotherapy (Part 2) as First Line Therapy in Stage IV Non-Small Cell Lung Cancer
Sponsor:
Bristol-Myers Squibb
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Non-Small-Cell Lung Cancer | View |
Keywords: